Author: Vivian Xie 11th June 2026

One of the most dramatic shifts in pharma over the past decade has been the growing use of biologics, which have found widespread uses across a vast range of therapies. From monoclonal antibodies to gene therapies and the revolutionary GLP-1 drugs reshaping obesity and diabetes treatment, these therapeutics may be advanced, but they also share a critical vulnerability: they can only work to their maximum strength in precise temperature-controlled conditions throughout the supply chain. Even a single, brief temperature excursion can render these life-saving medicines ineffective or unsafe, resulting in patient harm, regulatory consequences and substantial financial losses.

This state of affairs has elevated pharmaceutical cold chain logistics to a serious industry imperative. As transportation challenges intensify, accelerating demand for temperature-controlled pharmaceutical logistics solutions, there needs to be greater collaboration between pharmaceutical companies, logistics providers and technology innovators to ensure end-to-end cold chain integrity.

The Biologics Boom: Understanding the Scale of the Challenge

According to industry analysis, the global biologics market reached $487 billion in 2025 and is projected to expand to $1.24 trillion by 2035, representing a compound annual growth rate (CAGR) of 9.83%. This reflects biologics' superior efficacy for complex diseases, the maturation of manufacturing technologies and an increasingly robust pipeline of novel therapies targeting previously untreatable conditions.

Nature Biotechnology reports [1] that biologics now represent approximately 40% of drugs in development pipelines at major pharmaceutical companies, with this proportion expected to exceed 50% by the decade’s end. This shift from small to large-molecule biologics has fundamentally changed supply chain requirements, though the complexity extends beyond simple refrigeration.

Different biologics require different temperature ranges: standard refrigerated products must be maintained at between 2-8°C, frozen products require -20°C or colder and ultra-cold therapies like certain mRNA vaccines and cell therapies demand -80°C or even cryogenic temperatures below -150°C. Each range presents its own distinct logistical challenges, requiring specialised packaging, monitoring systems and handling protocols.

How the GLP-1 Revolution Revealed an Unprecedented Scale of Cold Chain Demands

The biologics boom started slowly and steadily, and few could have foreseen the unprecedented logistical demands brought about by the unprecedented popularity of GLP-1 drugs for diabetes and obesity. According to healthcare analysis from J.P. Morgan, [2] the GLP-1 market is projected to reach $150 billion by 2030, with patient numbers expanding from approximately 15 million in 2023 to an estimated 70 million by the start of the next decade.

However, the GLP-1 success story can only continue if logistics handlers are careful to maintain the strict temperature regulations needed to distribute the medication safely to the end user, at a range of 2-8°C refrigeration, with zero tolerance for freezing. Supply Chain Brain reports [3] that pharmaceutical companies have invested billions of dollars to expand their production lines, build new GLP-1 manufacturing facilities and strengthen their supply chain infrastructure to meet demand, pushing manufacturers and distributors to invest in expanded temperature-controlled packaging and monitoring systems.

The scale is staggering. With millions of patients requiring weekly or monthly injections, the volume of temperature-controlled shipments has increased exponentially. Healthcare logistics providers note [4] that GLP-1 distribution requires lane-specific packaging validation, pre-conditioned refrigerants, continuous data logging and last-mile packaging designed to handle patient-side delays. Any discrepancies in temperature tend to be traced back to gaps in carrier handoffs, insufficient supply of coolant for longer distribution lanes, or packaging which becomes invalidated as seasons change.

The oral GLP-1 formulations approved in late 2025 and early 2026 have somewhat eased cold chain pressures, eliminating refrigeration requirements for some products. However, as injectables remain the dominant formulation for these therapies, many believe this demand will continue to drive demand for cold chain logistics in the years ahead.

Cell and Gene Therapies: The Ultimate Cold Chain Challenge

If GLP-1 drugs represent cold chain logistics at their most large-scale, cell and gene therapies represent cold chain logistics at their most complex. These personalised medicines, which are often manufactured from a patient's own cells, require cryogenic temperatures throughout their journey from manufacturing facility to treatment centre, with any temperature excursion potentially destroying the therapy and eliminating the patient's treatment option.

According to Pharmaceutical Technology, [5] cell and gene therapies present unique challenges including ultra-low temperature requirements (often below -150°C) and time-critical delivery windows (some therapies have shelf lives measured in hours). There are also issues around bidirectional logistics, which requires patient material to be sent to manufacturing sites, before the finished therapy returns to treatment centres.

The stakes could not be higher. These therapies often represent patients' last options to treat life-threatening diseases, with individual therapy costs ranging from hundreds of thousands to millions of pounds. A cold chain failure could have lasting impact on a patient’s treatment and, in extreme cases, be a matter of life or death.

Temperature-Controlled Pharmaceutical Logistics Solutions

Meeting the logistical challenges raised by the biologics cold chain management process requires continuous innovation in packaging technologies, monitoring systems and logistics processes. The market for temperature-controlled pharmaceutical packaging has responded with remarkable advances that dramatically improve reliability whilst reducing costs and environmental impact.

As pointed out by Pharmaceutical Commerce, [6] modern solutions include vacuum insulation panels (VIPs) that provide superior thermal protection in compact formats, phase change materials (PCMs) engineered for specific temperature ranges and duration requirements and smart packaging with integrated sensors and connectivity for real-time monitoring. These innovations deliver tangible benefits. VIP-based shippers can maintain temperature control in compact configurations for over 96 hours, reducing shipping costs and environmental impact compared to traditional polystyrene-based solutions. Advanced PCMs provide more consistent temperature control with reduced coolant mass, improving payload capacity. Active containers enable intercontinental shipments of temperature-sensitive products that previously required air freight with multiple handoffs.

Sustainability has also become a critical consideration, with pharmaceutical companies seeking solutions that maintain product integrity whilst reducing environmental impact. Key focus areas for improving the environmental impact of cold chain logistics include reusable shipper programmes, recyclable insulation materials and right-sized packaging that eliminates waste.

Reliability Through Visibility with Real-Time Monitoring and Data Analytics

Technology advances extend beyond physical packaging to encompass monitoring and data systems that provide unprecedented supply chain visibility. According to coverage from IoT For All, [7] modern solutions combine IoT sensors, cloud connectivity, artificial intelligence analytics and blockchain-based chain of custody documentation to create comprehensive visibility and control.

These systems deliver multiple benefits: real-time alerts enable immediate intervention when temperature excursions occur, potentially saving products through rapid corrective action. Historical data analytics identify systemic issues, such as specific shipping lanes, carriers, or seasons that present elevated risk, enabling proactive improvements. Furthermore, automated documentation reduces administrative burden while ensuring compliance with local and international regulation.

Leading pharmaceutical companies now require their logistics providers to implement comprehensive monitoring systems with defined alert protocols, data retention policies and integration with pharmaceutical companies' quality systems. This visibility has become table stakes rather than a differentiator, with innovation now focused on predictive analytics that anticipate problems before they occur.

Staying Compliant: Navigating Global Regulatory Requirements

As cold chain logistics become more widespread, it falls to global authorities to implement stricter requirements for temperature control documentation, validation and deviation management. Companies must demonstrate validated cold chain processes, maintain comprehensive temperature records, investigate and document all temperature excursions and implement corrective and preventive actions (CAPA) for systemic issues.

The EMA's Good Distribution Practice (GDP) [8] guidelines, the US FDA's guidance on temperature-controlled distribution and the World Health Organization's temperature monitoring requirements create a complex regulatory environment that pharmaceutical companies and their logistics partners must navigate simultaneously. Non-compliance can result in product recalls, regulatory sanctions and reputational damage.

Successful compliance requires documented standard operating procedures, regular training and qualification of personnel, validated packaging and monitoring systems, robust deviation investigation processes and periodic audits of logistics partners. Many pharmaceutical companies now require their cold chain providers to maintain ISO 9001 quality management certification and demonstrate GDP compliance through third-party audits.

Building Partnerships That Protect Product Integrity

The complexity of modern pharmaceutical cold chain logistics makes it essential to make external partnerships to navigate these regulatory complexities. No single organisation possesses all the capabilities needed to ensure end-to-end temperature control across global distribution networks. Successful programmes require collaboration between pharmaceutical manufacturers, packaging suppliers, logistics providers, monitoring technology companies and regulatory consultants.

The Cold Chain & Logistics Zone at CPHI Milan facilitates these partnerships by bringing together the ecosystem in a concentrated environment designed for meaningful interaction. Structured partnering programmes let pharmaceutical companies schedule meetings with potential partners, with networking events and informal gathering spaces helping attendees foster the relationships that underpin successful collaborations.

For pharmaceutical companies committed to protecting their temperature-sensitive therapies, implementing temperature-controlled pharmaceutical logistics solutions that meet global regulatory requirements and building pharmaceutical cold chain logistics capabilities that support commercial success, CPHI Milan 2026 represents an essential investment in your cold chain strategy.

Meanwhile, as biologics and temperature-sensitive therapies continue their rapid growth, cold chain excellence has evolved from a compliance requirement to an edge in the marketplace. Pharmaceutical companies that implement robust, validated cold chain programmes can launch products in more markets, reduce product losses, accelerate time-to-patient and build stronger reputations with healthcare providers and patients.

Conversely, companies with inadequate cold chain capabilities face product recalls, regulatory sanctions, market access delays and reputational damage that can undermine commercial success. The stakes have never been higher and the margin for error continues to shrink as therapies become more complex and valuable.